Market Place
Sourcing Support
Apogee Therapeutics Closes Public Offering, Raises $403M
26 Mar 2026 //
GLOBENEWSWIRE
Apogee Data Drive Hype As Threat To Lilly, Sanofi Becomes Clear
23 Mar 2026 //
FIERCE BIOTECH
Apogee Therapeutics Plans $300M Public Offering
23 Mar 2026 //
GLOBENEWSWIRE
Apogee Announces Positive Phase 2 of Zumilokibart (APG777)
23 Mar 2026 //
GLOBENEWSWIRE
Apogee Therapeutics Reports Pipeline Progress, 2025 Outlook
02 Mar 2026 //
GLOBENEWSWIRE
Apogee Therapeutics Joins Guggenheim Biotech Summit 2026
05 Feb 2026 //
GLOBENEWSWIRE
Apogee Therapeutics Reports Promising Phase 1B Results
06 Jan 2026 //
GLOBENEWSWIRE
Apogee to Host Call on APG777 Interim Asthma Results
05 Jan 2026 //
GLOBENEWSWIRE
Apogee Therapeutics Reports Positive Phase 1 Interim Results
10 Nov 2025 //
GLOBENEWSWIRE
Apogee Therapeutics Updates Pipeline Progress & Q3 2025 Updates
10 Nov 2025 //
GLOBENEWSWIRE
Apogee Therapeutics Closes Public Offering, Raises $345M
10 Oct 2025 //
GLOBENEWSWIRE
Apogee Therapeutics Plans Underwritten Public Offering
08 Oct 2025 //
GLOBENEWSWIRE
Apogee Therapeutics Prices $300M Public Offering
08 Oct 2025 //
GLOBENEWSWIRE
Apogee Ph 2 APEX Trial Data of APG777 Revealed at EADV Congress
11 Sep 2025 //
GLOBENEWSWIRE
Apogee Therapeutics Reports Q2 2025 Financials, Pipeline Progress
11 Aug 2025 //
GLOBENEWSWIRE
Apogee Therapeutics Reports Phase 2 Win for Eczema Drug
07 Jul 2025 //
GLOBENEWSWIRE
Apogee Reports Positive Ph1b Data on Asthma Drug
12 May 2025 //
GLOBENEWSWIRE
Apogee Therapeutics Updates Business, Pipeline, Q1 2025 Finances
12 May 2025 //
GLOBENEWSWIRE
Apogee To Report APG990 Ph 1 Interim Data & Strategy Update
28 Feb 2025 //
GLOBENEWSWIRE
Apogee Doses 1st Patient in Ph 2 APEX Trial for Atopic Dermatitis
03 Feb 2025 //
GLOBENEWSWIRE
Apogee to Participate at Guggenheim SMID Cap Biotech Conference
29 Jan 2025 //
GLOBENEWSWIRE
Apogee Doses 1st Participants In APG333 Ph 1 Trial For Respiratory
10 Dec 2024 //
GLOBENEWSWIRE
Apogee Therapeutics Announces Agenda for Virtual R&D Day
29 Nov 2024 //
GLOBENEWSWIRE
Apogee Therapeutics to Host Inaugural Virtual R&D Day on Dec 2
18 Nov 2024 //
GLOBENEWSWIRE
Apogee Therapeutics Reports Q3 2024 Financial Results & Progress
12 Nov 2024 //
GLOBENEWSWIRE
Apogee Therapeutics to Participate in Nov Investor Conferences
04 Nov 2024 //
GLOBENEWSWIRE
Apogee Therapeutics Announces Phase 1 Trial Results For APG777
24 Oct 2024 //
GLOBENEWSWIRE
Apogee Announces Presentation at the ACAAI Annual Scientific Meeting
16 Oct 2024 //
GLOBENEWSWIRE
Apogee Therapeutics To Attend Stifel Immunology And Inflammation Summit
12 Sep 2024 //
GLOBENEWSWIRE
Apogee Therapeutics Appoints Jeff S. Hartness as CCO
09 Sep 2024 //
GLOBENEWSWIRE
Apogee Doses First Participants In APG990 Phase 1 Trial For Atopic Dermatitis
19 Aug 2024 //
GLOBENEWSWIRE
Apogee Therapeutics Reports Q2 2024 Results And Pipeline Progress
12 Aug 2024 //
GLOBENEWSWIRE
Apogee Therapeutics: Lisa Bollinger Joins Board Of Directors
28 May 2024 //
GLOBENEWSWIRE
Apogee Therapeutics to Participate in Upcoming June Investor Conferences
23 May 2024 //
GLOBENEWSWIRE
Apogee Doses First Patient In APG777 Phase 2 Atopic Dermatitis Trial
15 May 2024 //
GLOBENEWSWIRE
Apogee To Participate In BofA Healthcare Conference 2024
06 May 2024 //
GLOBENEWSWIRE
Apogee, Spyre founder launches its third biotech and heads straight to Nasdaq
03 Apr 2024 //
ENDPTS
Apogee Announces Positive Results from Ph 1 Healthy Volunteer Trial for APG777
05 Mar 2024 //
GLOBENEWSWIRE
Apogee Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 //
GLOBENEWSWIRE
Apogee Therapeutics to Participate in Upcoming November Investor Conferences
30 Oct 2023 //
GLOBENEWSWIRE
Apogee Announces Two Abstracts Accepted for Presentation at the EADV Congress
27 Sep 2023 //
GLOBENEWSWIRE
Apogee Therapeutics to Participate at the 2023 Stifel Virtual I&I Day
14 Sep 2023 //
GLOBENEWSWIRE
Apogee Appoints Mark C. McKenna as Chairman of its Board
21 Aug 2023 //
GLOBENEWSWIRE
Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 of APG777
07 Aug 2023 //
GLOBENEWSWIRE
Apogee Therapeutics to Participate in Upcoming August Investor Conferences
02 Aug 2023 //
GLOBENEWSWIRE
Apogee Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering
18 Jul 2023 //
GLOBENEWSWIRE
Apogee Therapeutics, Inc. Announces Pricing of Upsized Initial Public Offering
13 Jul 2023 //
GLOBENEWSWIRE
